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Abstract
Background: Percutaneous core needle biopsy (CNB) is considered to be the standard technique
for histological diagnosis of breast lesions. But, it is less reliable for diagnosing atypical ductal
hyperplasia (ADH). The purpose of the present study was to predict, based on clinical and
radiological findings, which cases of ADH diagnosed by CNB would be more likely to be associated
with a more advanced lesion on subsequent surgical excision.
Methods: Between February 2002 and December 2007, consecutive ultrasound-guided CNBs
were performed on suspicious breast lesions at Seoul St. Mary's Hospital. A total of 69 CNBs led
to a diagnosis of ADH, and 45 patients underwent follow-up surgical excision. We reviewed the
medical records and analyses retrospectively.
Results: Sixty-nine patients were diagnosed with ADH at CNB. Of these patients, 45 underwent
surgical excision and 10 (22.2%) were subsequently diagnosed with a malignancy (ductal carcinoma
in situ, n = 8; invasive cancer, n = 2). Univariate analysis revealed age ( 50-years) at the time of
core needle biopsy (p = 0.006), size (> 10 mm) on imaging (p = 0.033), and combined mass with
microcalcification on sonography (p = 0.029) to be associated with underestimation. When those
three factors were included in multivariate analysis, only age (p = 0.035, HR 6.201, 95% CI 1.135-
33.891) was an independent predictor of malignancy.
Conclusion: Age ( 50) at the time of biopsy is an independent predictive factor for breast cancer
at surgical excision in patients with diagnosed ADH at CNB. For patients diagnosed with ADH at
CNB, only complete surgical excision is the suitable treatment option, because we could not find
any combination of factors that can safely predict the absence of DCIS or invasive cancer in a case
of ADH.
Background
Percutaneous core needle biopsy (CNB) is the standard
technique for histological diagnosis of breast lesions. It
has become the procedure of choice to investigate suspi-
cious lesions of the breast and has been shown to be an
effective means to rule out cancer, alleviating the cost and
discomfort of surgery. Overall, CNB histological findings
are in agreement with surgical biopsy in more than 95%
of the cases [1-3]. But, CNB is less reliable for diagnosing
atypical ductal hyperplasia (ADH).
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ADH is a proliferative lesion of the breast epithelium,
which fulfils some but not all the criteria of low grade duc-
tal carcinoma in situ (DCIS) [4]. ADH carries a 4-5 times
increased risk of subsequent development of invasive car-
cinoma in either breast, [5,6] and there is genetic evidence
in cell populations associated with cancer suggesting it
may even be a direct precursor of malignancy[7]. Signifi-
cant discordance has been reported isn CNB diagnosis of
ADH, with 7%-87% of cases proving to be DCIS or inva-
sive carcinoma on subsequent surgical excision [8-14].
This problem arises from the difficulty in differentiating
between ADH and low grade DCIS on the small volume
of tissue obtained from core biopsy [15]. In addition, foci
of ADH may be present at the periphery of areas of DCIS
[16] and, thus, even an unequivocal diagnosis of ADH
does not preclude the presence of an adjacent and more
advanced lesion. Because of this underestimation (which
means presence of DCIS or invasive cancer) risk, some
authors have recommended a mandatory surgical biopsy,
while others have discussed options between surgery and
follow-up [17]. Identification of patients with ADH diag-
nosed by CNB who can be spared surgical excision is an
area of active investigation. However, the clinical, radio-
logic, and pathologic parameters on which to base this
decision have not been consistently identified.
The purpose of the present study was to predict, based on
clinical and radiological findings, which cases of ADH
diagnosed by CNB would be more likely to be associated
with a more advanced lesion on subsequent surgical exci-
sion.
Materials and methods
Between February 2002 and December 2007, 3476 con-
secutive ultrasound-guided CNBs were performed on sus-
picious breast lesions at the Seoul St. Mary's Hospital. A
total of 69 CNBs led to a diagnosis of ADH, and 45
patients underwent follow-up surgical excision. Seven
patients refused surgical excision and were only followed
up and 12 patients were transferred other hospital as per
their request while 5 were lost to follow-up. The defini-
tion employed for "histological underestimation" was a
lesion diagnosed as ADH at CNB that was revealed to har-
bor malignant foci at follow-up surgical excision, includ-
ing DCIS and invasive cancer. All patients in this study
underwent clinical and radiological examination, includ-
ing mammography and ultrasound. The radiological
appearance of the lesion was characterized according to
the American College of Radiology Breast Imaging Report-
ing and Data System lexicon and the final assessment cat-
egories. All lesions were evaluated for size on imaging and
presence of microcalcification. Lesion size was defined as
the greatest dimension on ultrasound imaging for most
patients, or mammography size for patients with micro-
calcification dominant lesions. Ultrasound-guided biop-
sies were used for sonographically visible lesions, and
were performed with patients in a supine or decubitus
position using high-resolution sonography. The biopsy
was performed using a device with a 14-gauge automated
needle or with an 11-gauge vacuum assisted biopsy
device. The core biopsy tissue sections were fixed in 10%
formaldehyde and embedded in paraffin. Each biopsy
specimen was stained with hematoxylin and eosin. The
biopsy slides were reviewed by experienced pathologists
and diagnosed according to the ADH diagnostic criteria of
the World Health Organization guidelines. The data were
analyzed using Chi-square and logistic regression, as well
as Fisher exact test for the small sample. P values < 0.05
were considered statistically significant.
Results
Sixty-nine patients were diagnosed with ADH at CNB. Of
these, 45 underwent surgical excision at our institution.
Of the 45 patients, 10 (22.2%) were diagnosed with a
malignancy after surgical excision (DCIS, n = 8; invasive
cancer, n = 2). Table 1 summarizes the underestimation
rates and distribution in all patients according to clinical,
radiological, and pathological variables, and compares
the accurate diagnoses (n = 35) and underestimations (n
= 10) according to patient, lesion, and biopsy variables.
Six (13.3%) underwent 11-gauge stereotactic vacuum
assisted biopsy because lesions were seen mainly by mam-
mography rather than ultrasound. Women in the accurate
diagnosis group were younger than those in the underes-
timation group (p = 0.003). Nine of the 39 ADH lesions
(23.1%) found with 14-gauge automated gun biopsies
were upgraded to carcinoma, and one of the six ADH
lesions (16.7%) found with 11-gauge vacuum-assisted
biopsies were upgraded to carcinoma. The underestima-
tion rate for the 11-gauge vacuum-assisted biopsy
(16.7%) was not significantly lower than that for the 14-
gauge automated gun biopsy (23.1%) (p = 0.725).
Univariate analysis revealed that age ( 50 years) at the
time of core needle biopsy (p = 0.006), size on imaging (>
10 mm; p = 0.033), and combined mass with microcalci-
fication on sonography (p = 0.029) were associated with
underestimation (Table 2). When those three factors were
included in multivariate analysis, only age at the time of
core needle biopsy (p = 0.035, HR 6.201, 95% CI 1.135-
33.891) was found to be an independent predictor of
malignancy, whereas size on imaging and combined mass
with microcalcification on sonography were negative pre-
dictors. (Table 3)
Discussion
In the present study, clinico-pathological and radiological
findings of ADH diagnosed by CNB were assessed to clar-
ify predictors that could be useful in distinguishing
between ADH and cancer containing DCIS. ADH is a bor-World Journal of Surgical Oncology 2009, 7:77 http://www.wjso.com/content/7/1/77
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Table 1: Pathologic results after surgical excision according to clinical, radiological and histological variables.
Pathology after excision Underestimation
rate (22.2%)
P value
(Chi-square)
Benign (n = 35) Malignancy (n = 10)
Age (years) < 50 28 (80%) 3 (30%) 9.7% 0.003
50 7 (20%) 7 (70%) 50%
Mass on MMG Yes 10 (32.3%) 4 (50%) 28.6% 0.351
No 21 (67.7%) 4 (50%) 16%
MIC on MMG Yes 8 (25.8%) 4 (50%) 33.3% 0.186
No 23 (74.2%) 4 (50%) 14.8%
Mass + MIC on MMG Yes 1 (3.1%) 2 (22.2%) 66.7% 0.52
No 31 (96.9%) 7 (77.8%) 18.4%
Lesion size 1 cm 23 (69.7%) 3 (30%) 11.5% 0.024
> 1 cm 10 (30.3%) 7 (70%) 41.2%
Mass on USG Yes 27 (77.1%) 9 (90%) 25% 0.370
No 8 (22.9%) 1 (0%) 11.1%
MIC USG Yes 2 (5.7%) 3 (30%) 60% 0.031
No 33 (94.3%) 7 (70%) 17.5%
Mass + MIC on USG Yes 1 (2.9%) 3 (30%) 75% 0.008
No 34 (97.1%) 7 (70%) 17.1%
Needle size 14 Gauge 30 (85.7%) 9 (90%) 23.1% 0.725
11 Gauge 5 (14.3%) 1 (0%) 16.7%
Number of Cores  5 30 (85.7%) 8 (80%) 21.1% 0.660
> 5 5 (14.3%) 2 (20%) 28.6%
MMG: mammogram, MIC: microcalcification, USG: ultrasonography
Table 2: Results of univariate analysis
HR 95% CI P-value
Age 9.333 1.911-45.583 0.006
Mass MMG 2.1 0.434-10.168 0.357
MIC MMG 2.875 0.579-14.275 0.196
Mass + MIC MMG 8.857 0.701-111.937 0.092
Lesion size 5.367 1.147-25.105 0.033
Mass USG 2.667 0.292-24.345 0.385
MIC USG 4.571 0.758-27.577 0.097
Mass + MIC USG 14.571 1.315-161.418 0.029
Needle size 1.50 0.155-14.557 0.727
Number of cores 1.50 0.244-9.219 0.662
HR: hazard ratio; CI: confidence interval; MMG: mammogram; MIC: 
microcalcification; USG: ultrasonography
Table 3: Results of Multivariate analysis.
HR 95% CI P-value
Age 6.201 1.135-33.891 0.035
Lesion size 2.878 0.474-17.465 0.250
Mass + MIC USG 4.571 0.288-72.609 0.281
HR: hazard ratio; CI: confidence interval; MMG: mammogram; MIC: 
microcalcification; USG: ultrasonographyWorld Journal of Surgical Oncology 2009, 7:77 http://www.wjso.com/content/7/1/77
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derline lesion on histology that is difficult to distinguish
from low grade DCIS on the small tissue sample provided
by CNB. Because of this difficulty, clinico-pathologic and
radiologic findings that can help discriminate between
ADH and DCIS are valuable in planning patient manage-
ment.
Although some variables like lesion size, combined mass,
and microcalcification on sonography also tended to
increased underestimation, only age at the time of biopsy
( 50 years) was presently determined to be an independ-
ent predictive factor for breast cancer at surgical excision
in patients with diagnosed ADH at CNB. Consistent with
our findings, Ko et al [18] observed an increase in under-
estimation rates in subjects aged 50 years and older,
microcalcification on mammography and, lesion size >
15 mm.
Several studies have examined various mammographic,
clinical, and pathological factors that may predict the
presence of a more significant lesion on surgical excision
after a CNB diagnosis of ADH [12,19-21]. It is believed
that the variability of cancer rates depends on the size and
features of the mammographic lesion, size of the biopsy
needle, extent and completeness of sampling of the mam-
mographic target lesion, histological criteria used to diag-
nose ADH versus DCIS and/or usual hyperplasia, and the
threshold for surgical excision.
Use of vacuum assistance and more extensive sampling
have improved the underestimation of carcinoma on sur-
gical biopsy after a diagnosis of ADH on CNB from 33%-
48% [2,21] to 7%-35% [14,22-25]. Although reduced
underestimation with use of an 11-gauge vacuum-assisted
device is explained by larger sample volumes, the number
of specimens obtained presently appeared not to be corre-
lated with a lower rate of underestimation. These results
are similar to those of a previous study [12], in which the
investigators found that specimen numbers per lesion did
not correlate with underestimation, but that complete
lesion removal did correlate with degree of underestima-
tion. These findings indicate that targeting precision is
more important than sample numbers. Further studies
with more cases are needed to determine whether com-
plete lesion removal at sonographically guided 11-gauge
vacuum-assisted biopsy can reduce the rate of underesti-
mation of ADH.
Jackman et al, [26] recognized that as the maximum diam-
eter of the mammographic lesion increased, so does the
rate of ADH underestimation. Also, in the present study,
lesion size on imaging of > 1 cm increased underestima-
tion rates. However, lesion size was not an independent
predictor upon multivariate analysis.
Microcalcification with or without a mass has been
reported to be the most common finding for both ADH
(58% 88%) and DCIS (68% 98%) [8,27-29]. On histolog-
ical examination, Helvie et al [10] found that the calcifica-
tions in mammary ducts within areas of ADH, without
cell necrosis. In DCIS, the calcifications develop in secre-
tions and are dystrophic calcifications secondary to
necrotic tumor cells [30,31]. These histological differences
could potentially be associated with different mammo-
graphic findings. But, those detailed variables were not
addressed in the present study. Presently, only the com-
bined sonographic finding of mass and microcalcifica-
tions was a significant predictive factor for
underestimation in the univariate analysis. It has been
suggested that microcalcification on mammography is an
independent predictor of malignancy at follow-up surgi-
cal excision in patients diagnosed with ADH at CNB [18].
Our results did not reveal statistical significance in this
regard.
Limitations of the present study include its retrospective
nature and that it did not involve a randomized series of
patients. Furthermore, 24 (34.8%) of the 69 ADH cases
did not undergo surgical excision and were therefore
excluded. It is possible that cases with a lower possibility
of malignancy were recommended for imaging follow-up
rather than surgical excision, which could affect the
underestimation rate and other results.
Conclusion
Only age at the time of biopsy ( 50 years) is an independ-
ent predictive factor for breast cancer at surgical excision
in patients with diagnosed ADH at CNB. Identification of
patients with ADH diagnosed by CNB who can be spared
surgical excision is an area of active investigation. How-
ever, at present, clinical, radiologic, and pathologic factors
on which to base this decision have not been consistently
identified. So, for patients diagnosed with ADH at CNB,
only complete surgical excision is a suitable treatment
option because we could not find any combination of fac-
tors that can safely predict the absence of DCIS or invasive
cancer in a case of ADH.
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